This is an aggregated industry headline. Read the full story at BioPharma Dive →
Pfizer drug acquired in Seagen deal disappoints in lung cancer study
The setback dims the outlook for a medicine Pfizer sees as an important contributor going forward, though some analysts are optimistic about the drug's chances in another trial.
By BioPharma Dive
· Jun 23, 2026
· via BioPharma Dive
Image: BioPharma Dive
RxInsider combines reported facts with industry analysis and informed inference. Forward-looking reads, market commentary, and interpretive framing reflect analysis of available reporting and known facts, not confirmed outcomes.
Tags
theweekformat:headlineheadlineBioPharma Dive
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from The Week
All The Week →
The WeekFiercePharma ↗
Julianne Hough is the new face of Revance's Botox rival Daxxify. The company has enlisted the dancer, actress …
The WeekFierceBiotech ↗
An under-the-radar Bay Area biotech has brought in a $190 million series B with the goal of hatching a clutch …
The WeekBriefing
Serapha Bio forms via Boundless Bio reverse merger, backed by $230M to advance SERP-01, a China-derived base-e…